Carnegie Investment Counsel Acquires New Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Carnegie Investment Counsel acquired a new stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) in the third quarter, HoldingsChannel reports. The fund acquired 2,916 shares of the company’s stock, valued at approximately $204,000.

Other institutional investors have also modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF during the 2nd quarter valued at about $26,000. GPS Wealth Strategies Group LLC bought a new position in Invesco Biotechnology & Genome ETF in the 2nd quarter worth about $30,000. UMB Bank n.a. bought a new position in Invesco Biotechnology & Genome ETF in the 2nd quarter worth about $31,000. Covestor Ltd grew its position in Invesco Biotechnology & Genome ETF by 24.2% in the 1st quarter. Covestor Ltd now owns 955 shares of the company’s stock worth $62,000 after purchasing an additional 186 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new position in Invesco Biotechnology & Genome ETF in the 1st quarter worth about $232,000.

Invesco Biotechnology & Genome ETF Trading Up 0.2 %

NYSEARCA PBE opened at $70.13 on Wednesday. Invesco Biotechnology & Genome ETF has a 52 week low of $52.47 and a 52 week high of $72.72. The stock has a market cap of $283.31 million, a price-to-earnings ratio of 17.12 and a beta of 0.88. The company has a 50-day moving average price of $69.90 and a two-hundred day moving average price of $66.50.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.